A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate

  1. Lorena Sanchez Felipe
  2. Thomas Vercruysse
  3. Sapna Sharma
  4. Ji Ma
  5. Viktor Lemmens
  6. Dominique van Looveren
  7. Mahadesh Prasad Arkalagud Javarappa
  8. Robbert Boudewijns
  9. Bert Malengier-Devlies
  10. Suzanne F. Kaptein
  11. Laurens Liesenborghs
  12. Carolien De Keyzer
  13. Lindsey Bervoets
  14. Madina Rasulova
  15. Laura Seldeslachts
  16. Sander Jansen
  17. Michael Bright Yakass
  18. Osbourne Quaye
  19. Li-Hsin Li
  20. Xin Zhang
  21. Sebastiaan ter Horst
  22. Niraj Mishra
  23. Lotte Coelmont
  24. Christopher Cawthorne
  25. Koen Van Laere
  26. Ghislain Opdenakker
  27. Greetje Van de Velde
  28. Birgit Weynand
  29. Dirk E. Teuwen
  30. Patrick Matthys
  31. Johan Neyts
  32. Hendrik Jan Thibaut
  33. Kai Dallmeier
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-191. We employed the live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express the prefusion form of the SARS-CoV-2 Spike antigen. In mice, the vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response. In a stringent hamster SARS-CoV-2 challenge model2, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate.

Related articles

Related articles are currently not available for this article.